World Investment Advisors Buys Shares of 10,014 Halozyme Therapeutics, Inc. $HALO

World Investment Advisors purchased a new position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 10,014 shares of the biopharmaceutical company’s stock, valued at approximately $674,000.

Several other hedge funds and other institutional investors have also modified their holdings of the company. Empowered Funds LLC purchased a new stake in shares of Halozyme Therapeutics during the 1st quarter worth about $755,000. Acadian Asset Management LLC bought a new stake in shares of Halozyme Therapeutics in the 1st quarter valued at approximately $195,000. Hsbc Holdings PLC increased its holdings in Halozyme Therapeutics by 117.1% in the second quarter. Hsbc Holdings PLC now owns 10,102 shares of the biopharmaceutical company’s stock worth $522,000 after buying an additional 5,448 shares during the last quarter. EverSource Wealth Advisors LLC increased its holdings in Halozyme Therapeutics by 6.9% in the second quarter. EverSource Wealth Advisors LLC now owns 2,685 shares of the biopharmaceutical company’s stock worth $140,000 after buying an additional 174 shares during the last quarter. Finally, Baird Financial Group Inc. raised its position in Halozyme Therapeutics by 6.2% during the second quarter. Baird Financial Group Inc. now owns 11,090 shares of the biopharmaceutical company’s stock valued at $577,000 after acquiring an additional 650 shares in the last quarter. 97.79% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Halozyme Therapeutics

In other Halozyme Therapeutics news, CEO Helen Torley sold 20,000 shares of the stock in a transaction on Monday, June 1st. The shares were sold at an average price of $67.58, for a total value of $1,351,600.00. Following the completion of the sale, the chief executive officer directly owned 767,780 shares of the company’s stock, valued at $51,886,572.40. This represents a 2.54% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bernadette Connaughton sold 1,625 shares of the firm’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $66.21, for a total transaction of $107,591.25. Following the completion of the sale, the director owned 43,669 shares in the company, valued at $2,891,324.49. This represents a 3.59% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 93,250 shares of company stock valued at $6,299,746. Corporate insiders own 2.50% of the company’s stock.

Halozyme Therapeutics Stock Performance

HALO opened at $68.99 on Tuesday. The company has a quick ratio of 2.33, a current ratio of 2.76 and a debt-to-equity ratio of 8.81. The stock’s 50 day moving average price is $68.06 and its two-hundred day moving average price is $68.66. The firm has a market capitalization of $8.18 billion, a P/E ratio of 24.82, a price-to-earnings-growth ratio of 0.28 and a beta of 0.88. Halozyme Therapeutics, Inc. has a 12-month low of $51.06 and a 12-month high of $82.22.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings results on Monday, May 11th. The biopharmaceutical company reported $1.60 EPS for the quarter, topping analysts’ consensus estimates of $1.54 by $0.06. The company had revenue of $376.71 million during the quarter, compared to analyst estimates of $358.60 million. Halozyme Therapeutics had a return on equity of 187.91% and a net margin of 23.13%.The company’s quarterly revenue was up 42.2% compared to the same quarter last year. During the same period in the previous year, the company earned $1.11 earnings per share. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. On average, equities analysts forecast that Halozyme Therapeutics, Inc. will post 7.54 earnings per share for the current year.

Analyst Ratings Changes

Several analysts have commented on the stock. UBS Group reissued a “buy” rating and issued a $90.00 target price on shares of Halozyme Therapeutics in a research report on Wednesday, June 3rd. Weiss Ratings upgraded shares of Halozyme Therapeutics from a “hold (c)” rating to a “buy (b-)” rating in a report on Tuesday, May 12th. HC Wainwright reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a research note on Tuesday, June 16th. Wall Street Zen upgraded shares of Halozyme Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, May 16th. Finally, Benchmark reissued a “buy” rating on shares of Halozyme Therapeutics in a research report on Wednesday, June 3rd. Eight analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $81.60.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.